Impact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: an optical coherence tomography analysis
- 26 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal – Cardiovascular Imaging
- Vol. 20 (8), 916-924
- https://doi.org/10.1093/ehjci/jey210
Abstract
Aims Second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) is an alternative novel device for treating coronary lesions. However, the relationship between in-scaffold dimensions after implantation of DREAMS 2G and vessel healing and luminal results at follow-up is unknown. The aim of this study is, therefore, to investigate whether the expansion index after implantation of DREAMS 2G as assessed by optical coherence tomography (OCT) impacts late luminal status and healing of the vessel wall. Methods and results This study comprises of a total 65 out of 123 patients who were enrolled in the BIOSOLVE-II trial. We assessed both qualitative and quantitative OCT findings and the expansion index of DREAMS 2G after implantation frame by frame using OCT. Expansion index was defined as minimum scaffold area/mean reference lumen area. The over-expansion group was also defined with expansion index >1.0. The total number of analysed frames at post-procedure and 6-month follow-up was 8243 and 8263 frames, respectively. At 6-month follow-up, in-scaffold healing was documented by the reduction of 82% in dissections, 93% in attached intra-luminal mass (ILM), 65% in non-attached ILM, and 76% in jailed side branch. The over-expansion group had significantly greater in-scaffold luminal volume loss (LVL) compared with the non-over-expansion group [over-expansion: 35.0 (18.5–52.1) mm3 vs. non-over-expansion: 21.0 (11.6–37.9) mm3, P = 0.039]. Conclusion Excellent in vivo healing process after implantation of DREAMS 2G was observed at 6 months. We found that higher expansion indices were associated with higher in-scaffold LVL at 6 months assessed by OCT.Keywords
Funding Information
- BIOTRONIK AG
This publication has 18 references indexed in Scilit:
- Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized TrialsCell Metabolism, 2018
- In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris — DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man TrialInternational Journal of Cardiology, 2017
- Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold ImplantationJournal of the American College of Cardiology, 2017
- Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-IIIEuroIntervention, 2017
- Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients withde novocoronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trialEuropean Heart Journal, 2016
- Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trialThe Lancet, 2015
- Current Status of Bioresorbable Scaffolds in the Treatment of Coronary Artery DiseaseJournal of the American College of Cardiology, 2014
- Assessing Bioresorbable Coronary DevicesJACC: Cardiovascular Imaging, 2014
- Bioresorbable scaffolds: rationale, current status, challenges, and futureEuropean Heart Journal, 2013
- Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography StudiesJournal of the American College of Cardiology, 2012